RTSM Manages Clinical IP Dispensation In Schizophrenia Study

Faced with the challenge of managing the dispensation of their investigational product (IP) across diverse patient subgroups with varying visit schedules, a pharmaceutical company sought to ensure optimal distribution and minimize wastage. During their Phase II study for schizophrenia, the pharma opted for Signant SmartSignals RTSM solution to achieve the following:

1. Sustain study equilibrium among numerous strata and subgroups.
2. Prevent duplication in IP allocation to individual subjects.
3. Efficiently handle supply returns and disposals as required, including instances of early patient termination.

For additional insights and more information about the clinical trial, access the case study provided below, and explore Signant's RTSM page for additional information.